Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NKTR Nektar Therapeutics
- Stocks
- Healthcare
- NASDAQ: NKTR
Price (delayed)
$25.76
Market cap
$319.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.45
Enterprise value
$381.05M
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines.
Highlights
Nektar Therapeutics's gross margin has increased by 22% YoY and by 8% from the previous quarter
The debt has decreased by 12% YoY and by 2.2% QoQ
Nektar Therapeutics's EPS has increased by 32% YoY but it has decreased by 9% QoQ
The net income has grown by 24% year-on-year but it has declined by 12% since the previous quarter
Nektar Therapeutics's equity has shrunk by 89% YoY and by 77% QoQ
Nektar Therapeutics's quick ratio has decreased by 45% YoY and by 26% from the previous quarter
Key stats
What are the main financial stats of NKTR
Market
Valuations
Earnings
Shares outstanding
12.41M
Market cap
$319.6M
Enterprise value
$381.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
23.26
Price to sales (P/S)
4.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.37
Revenue
$87.25M
Gross profit
$65.1M
Operating income
-$114.31M
Net income
-$133.04M
EBIT
-$105.64M
EBITDA
-$102.43M
Free cash flow
-$112.8M
Per share
Balance sheet
Liquidity
EPS
-$9.45
EPS diluted
-$9.45
Free cash flow per share
-$8.02
Book value per share
$1.11
Revenue per share
$6.2
TBVPS
$18.22
Total assets
$256.24M
Total liabilities
$242.5M
Debt
$100.34M
Equity
$13.74M
Working capital
$158.98M
Debt to equity
7.3
Current ratio
3.24
Quick ratio
3.08
Net debt/EBITDA
-0.6
Margins
Efficiency
Dividend
EBITDA margin
-117.4%
Gross margin
74.6%
Net margin
-152.5%
Operating margin
-131%
Return on assets
-43.9%
Return on equity
-262.1%
Return on invested capital
-34.2%
Return on capital employed
-57%
Return on sales
-121.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NKTR stock price
How has the Nektar Therapeutics stock price performed over time
Intraday
-13.21%
1 week
202.7%
1 month
154.55%
1 year
50.64%
YTD
84.66%
QTD
152.55%
Financial performance
How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$87.25M
Gross profit
$65.1M
Operating income
-$114.31M
Net income
-$133.04M
Gross margin
74.6%
Net margin
-152.5%
The operating income is up by 30% year-on-year but it is down by 9% since the previous quarter
The operating margin has grown by 28% YoY but it has contracted by 23% from the previous quarter
The net margin has decreased by 26% QoQ but it has increased by 22% YoY
The net income has grown by 24% year-on-year but it has declined by 12% since the previous quarter
Price vs fundamentals
How does NKTR's price correlate with its fundamentals
Growth
What is Nektar Therapeutics's growth rate over time
Valuation
What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
23.26
P/S
4.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.37
Nektar Therapeutics's EPS has increased by 32% YoY but it has decreased by 9% QoQ
Nektar Therapeutics's equity has shrunk by 89% YoY and by 77% QoQ
The stock's P/S is 80% more than its last 4 quarters average of 2.3 but 63% less than its 5-year quarterly average of 11.2
The revenue has contracted by 11% from the previous quarter and by 3.2% YoY
Efficiency
How efficient is Nektar Therapeutics business performance
Nektar Therapeutics's ROE has plunged by 129% YoY and by 74% from the previous quarter
The return on invested capital has declined by 31% since the previous quarter
Nektar Therapeutics's return on sales has decreased by 31% QoQ but it has increased by 28% YoY
NKTR's ROA is down by 25% from the previous quarter and by 8% YoY
Dividends
What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NKTR.
Financial health
How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's total assets is 6% more than its total liabilities
The company's current ratio fell by 47% YoY and by 24% QoQ
Nektar Therapeutics's quick ratio has decreased by 45% YoY and by 26% from the previous quarter
Nektar Therapeutics's equity has shrunk by 89% YoY and by 77% QoQ
The debt has decreased by 12% YoY and by 2.2% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.